Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies

“We are planning to be able to treat over 2000 patients next year. So by commissioning additional Cocoons from Lonza, with this state-of-the-art technology, our yield has been 100%.”

The HER2-targeted T-cell antigen coupler (TAC) T-cell therapy TAC01-HER2 (Triumvira Immunologics) demonstrated early signs of clinical activity and a manageable safety profile, according to updated data from the phase 1/2 TACTIC-2 study (NCT04727151). A patient with stage 4b gastric cancer treated with TAC01-HER2 had a partial response and those in cohort 2 experienced a disease control rate of 75%.

The trial will be enrolling in its phase 2 portion in the beginning of 2023. These data were presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, in Paris, France, and virtually, by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute.

CGTLive spoke with the senior author of the poster, Deyaa Adib, MD, who is chief medical officer of Triumvira Immunologics, to learn more about Triumvira’s programs and technologies. He discussed an upcoming investigational new drug application (IND) submission in 2023 for claudin 18.2-positive cancers including gastric, pancreatic, ovarian, and lung cancers. He also discussed Lonza’s Cocoon technology that Triumvira is using in its programs and its advantages in the space.

Click here to read more coverage of ESMO Congress 2022.

REFERENCE

Schlechter BL, Ileana Dumbrava EE, Olson D, et al. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Presented at: ESMO Congress 2022, September 9-13, Paris, France. Poster #778TiP